FBN Securities raises Zscaler stock price target on strong Q4 beat

Zscaler’s Q4 FY2026 results helped analysts turn more constructive: revenue rose 25% YoY to $898.2M, beating consensus by 2.4%, while gross margin held at 76.8%. FBN Securities raised its price target to $190 (from $175) on strong performance and accelerated organic net new ARR of $232M, growing 17% YoY. Offsetting caution remains as FY2027 ARR guidance implies ~4% net new growth and capex is set to rise to ~13% of revenue from 8.3%.

Analysis

ZS is shifting from a “good quarter” story to a durability test. The market will care less about the print itself than whether the recent acceleration in net-new ARR can survive a tougher rate backdrop and slower IT spend normalization. If the company is already guiding to much lower forward growth while margins peak, the multiple should be thought of as a premium-growth-asset multiple, not an error-free compounding machine; that creates downside if investors start underwriting only low-teens growth.

The competitive read-through is mixed for the cyber group. ZS’s momentum should pressure adjacent zero-trust and SASE vendors to defend share with better packaging or pricing, but it also raises the bar for peers like PANW, CRWD, and FTNT to show that their own growth is not just budget reallocation. The second-order risk is that rising capex and sales reinvestment signal a heavier go-to-market and infrastructure burden; if that spend is defensive rather than expansionary, free-cash-flow quality can deteriorate before revenue momentum does.

Contrarian view: the consensus is likely over-focusing on margin expansion and underweighting the growth deceleration embedded in forward guidance. In a higher-rate tape, a stock can still work on a relative basis if it keeps outperforming software, but absolute upside may be capped unless the next two quarters confirm reacceleration. What would falsify the thesis is any sign that organic billings/ARR growth drops back toward the high-single-digit zone or that reinvestment continues without a corresponding improvement in retention and expansion.

Key Decisions for Investors

• Tactically buy ZS on post-earnings pullbacks, but only if it holds the earnings gap and relative strength versus IGV over the next 1-3 weeks; upside is a re-rating toward the latest analyst targets, while a break of post-print support would imply the market is fading the growth narrative.
• Pair trade: long ZS / short IGV for 1-3 months to isolate idiosyncratic cyber reacceleration against the broader software-duration headwind from higher Fed hike odds; this is a cleaner expression than outright beta exposure.
• If long-only, size ZS as a momentum trade rather than a core compounder until the next guide: add only after confirmation that forward ARR growth does not inflect lower; otherwise the stock likely trades as a premium multiple with limited multiple expansion.
• Watch PANW and CRWD for sympathy moves: if ZS strength is accompanied by weaker relative performance in peers, that suggests rotation into the name rather than an improving sector tape, which lowers follow-through quality.
• Set a thesis-falsification alert if ZS underperforms the software index by >5% over the next month or if the next quarter implies continued capex ramp without clear ARR acceleration; that would argue for taking profits or hedging with IGV.